Saluda Medical Inc.（简称Saluda Medical）宣布，其创新产品Eva™传感技术已正式获得欧洲监管机构的批准。这项突破性技术同时也在澳大利亚获得官方认可，标志着公司在神经调控领域取得重要进展。Eva™技术能够实时监测并自动调节脊髓刺激疗法的输出，为慢性疼痛患者提供更精准、个性化的治疗方案。此次获批将助力Saluda Medical进一步拓展全球市场，为更多患者带来福音。
Saluda Medical Inc.（简称Saluda Medical）宣布，其创新产品Eva™传感技术已正式获得欧洲监管机构的批准。这项突破性技术同时也在澳大利亚获得官方认可，标志着公司在神经调控领域取得重要进展。Eva™技术能够实时监测并自动调节脊髓刺激疗法的输出，为慢性疼痛患者提供更精准、个性化的治疗方案。此次获批将助力Saluda Medical进一步拓展全球市场，为更多患者带来福音。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.